Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
PBFT02 demonstrated durable, elevated CSF PGRN levels and early evidence of reduction in plasma NfL levels, a disease progression biomarker, compared to published natural history data Evaluating...
Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data expected in 1H25 Updated interim data from...
PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0175 | -2.89256198347 | 0.605 | 0.624 | 0.5596 | 122667 | 0.60242789 | CS |
4 | -0.1021 | -14.8056844548 | 0.6896 | 1.01 | 0.5596 | 705490 | 0.76981306 | CS |
12 | -0.0441 | -6.98226725776 | 0.6316 | 1.33 | 0.451 | 821212 | 0.858602 | CS |
26 | -0.3295 | -35.9323882225 | 0.917 | 1.33 | 0.451 | 518204 | 0.81379945 | CS |
52 | -0.3625 | -38.1578947368 | 0.95 | 1.79 | 0.451 | 380607 | 0.9668558 | CS |
156 | -4.1125 | -87.5 | 4.7 | 5.33 | 0.451 | 341424 | 1.35669326 | CS |
260 | -21.6825 | -97.361921868 | 22.27 | 38.23 | 0.451 | 327356 | 6.78194631 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.